Search
Search Results
-
The Cancer Stem Cell and Tumour Progression
Tumour stem cells result from genetic or chromosomal changes in normal tissue stem cells, i.e. cells with self-renewal capability. Subsequent tumour...
-
Tumour-derived small extracellular vesicles contribute to the tumour progression through resha** the systemic immune macroenvironment
BackgroundTumour-derived small extracellular vesicles (sEVs) play a crucial role in cancer immunomodulation. In addition to tumour immune...
-
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance
BackgroundCDC6 is an oncogenic protein whose expression level fluctuates during the cell cycle. Although several E3 ubiquitin ligases responsible for...
-
Sp1 promotes tumour progression by remodelling the mitochondrial network in cervical cancer
BackgroundCervical cancer remains one of the most prevalent cancers worldwide. Accumulating evidence suggests that specificity protein 1 (Sp1) plays...
-
TRPV1 inhibition suppresses non-small cell lung cancer progression by inhibiting tumour growth and enhancing the immune response
PurposeTRPV1 is a nonselective Ca 2+ channel protein that is widely expressed and plays an important role during the occurrence and development of...
-
Tumour-on-a-Chip: Perfusion Systems to Model the Extracellular Breast Tumour Microenvironment—From Tumour Progression to Metastasis Formation
The integration of three-dimensional (3D) tumour models in perfusion systems has provided new tools to study cancer and metastasis. Such systems are...
-
Differential expression of the circadian clock network correlates with tumour progression in gliomas
BackgroundGliomas are tumours arising mostly from astrocytic or oligodendrocytic precursor cells. These tumours are classified according to the...
-
Oncofetal reprogramming in tumour development and progression
Embryonic development is characterized by rapidly dividing cells, cellular plasticity and a highly vascular microenvironment. These features are...
-
Role of Tumour-Associated Macrophages in Colon Cancer Progression and Its Therapeutic Targeting
Cancer tissues are invariably infiltrated by cells of the immune system, and macrophages constitute the major portion of these. Experimental pieces...
-
The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients
BackgroundThe disruption of epithelial features represents a critical step during breast cancer spread. In this context, the dysregulation of...
-
METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2—breast cancer
BackgroundChemotherapy is an important strategy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative...
-
-
A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma
BackgroundLate diagnosis is one of the major confounders in oral squamous cell carcinoma (OSCC). Despite recent advances in molecular diagnostics, no...
-
MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2
BackgroundThe mechanism of recurrence and metastasis of hepatocellular carcinoma (HCC) is complex and challenging. Methyl-CpG binding domain protein...
-
The role of ROS in tumour development and progression
Eukaryotic cells have developed complex systems to regulate the production and response to reactive oxygen species (ROS). Different ROS control...
-
The dynamic role of platelets in cancer progression and their therapeutic implications
Systemic antiplatelet treatment represents a promising option to improve the therapeutic outcomes and therapeutic efficacy of chemotherapy and...
-
Loss of two-pore channel 2 function in melanoma-derived tumours reduces tumour growth in vivo but greatly increases tumour-related toxicity in the organism
BackgroundMelanoma, a severe form of skin cancer, poses significant health risks due to its aggressive nature and potential for metastasis. The role...
-
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression
Heterogeneity within a tumour increases its ability to adapt to constantly changing constraints, but adversely affects a patient’s prognosis, therapy...
-
Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification
N6-methyladenosine (m6A), a posttranscriptional regulatory mechanism, is the most common epigenetic modification in mammalian mRNA. M6A modifications...
-
METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma
BackgroundClear-cell renal-cell carcinoma (ccRCC) is one of the leading causes of tumour-related death worldwide. Methyltransferase-like 14 (METTL14)...
